

H2O: Strengthening the patient voice in health care

Facts & figures

START DATE:

01/10/2020

END DATE:

30/09/2025

CALL:

IMI2 – Call 18

GRANT AGREEMENT NUMBER:

945345

TYPE OF ACTION:

RIA (Research and Innovation Action)

TOTAL COST:

20.6 million €

What is H2O?

The Health Outcomes Observatory (H2O) is a strategic alliance between the public and private sectors to create an **unprecedented, standardised data governance and infrastructure system** across Europe that **incorporates patients' experiences and preferences** in decisions affecting their individual health care and those of the entire patient community.

This will materialise in a network of Observatories that will allow an ethical and legal use of data to:

- Measure outcomes more effectively.
- Facilitate personalised treatments.
- Enhance health research prospects.
- Promote value-based approaches in health care systems.

Our mission

H2O is set to **transform the use of patient-reported information in health care**, enrich the interaction between patients and health care providers and, as a result, drive better outcomes for patients. The project will **fill an important gap** as outcomes reported by patients are not usually incorporated in a comprehensive and systematic way into the decision-making process affecting their individual clinical care.

H2O plans to:

- Set up national Observatories, initially in 4 countries and focusing on 3 disease areas, before extending the concept across Europe and to other diseases.
- Adopt user friendly digital tools and processes for patients and providers to share relevant information.
- Empower patients with digital tools to better manage their health care.

Who participates in H2O?

The Consortium brings together 13 leading Academic institutions, SMEs and patients' organisations and 10 EFPIA companies. The project is led by Takeda Pharmaceutical and the Medical University of Vienna (MUW).



Why is H2O important?

H2O is creating an innovative governance and infrastructure model to unleash the potential of health data in Europe, whilst making sure that patient's privacy rights are protected and data, as an essential resource, is better safeguarded and used in the interest of society.

How will Health Authorities benefit?

Health care systems are faced with the challenge of optimising their resources to deliver the best care.

H2O will allow health authorities to:

- **Supplement existing data sources** to develop a **deeper understanding** of the burden of disease and the **performance of the healthcare system** within a country to identify areas for potential improvement.
- **Inform HTA analyses and processes** with patient perspectives, including PROs and PROMs from patients within their jurisdiction and, where appropriate, beyond to permit continual **adjustments to health care** approaches, making continuous **value based health care** improvements a reality.
- Enable health authorities to **compare** different **patient pathways** and **select the most efficient** ones, optimising patient outcomes and costs.
- Promote **outcomes-based pricing and reimbursement negotiations**, including outcomes-based contracting.

What are the Observatories?


The national Observatories are **independent, not-for-profit, legal entities** created for **data collection, analysis and evidence sharing** to inform clinical practice and healthcare decisions.

These ethically and legally sound national Observatories are initially being created in **four countries** –the Netherlands, Austria, Germany and Spain– covering **three diseases** –cancer, diabetes and IBD (Inflammatory Bowel Disease)–.

They operate under a **governance model** that guarantees **data protection** under national and European jurisdictions. These independent entities (Observatories) guard data on behalf of patients, who keep control of their own data being used for individual and collective care, research or the evaluation of new technologies.

These entities connect to a **pan-European Observatory** to facilitate interoperability, guide reproducibility in other countries, and promote the benefit of measuring and using patient-centred outcomes at regional, national, European, and global levels.

This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 945345-2. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA and Trial Nation and JDRF. This document reflects the views of the authors and neither IMI nor the European Union, EFPIA or any Associated Partners are liable for any use that may be made of the information contained herein.



NOVARTIS

abbvie

Roche

MEDICAL UNIVERSITY OF VIENNA

teawit RESEARCH

Takeda

Medtronic

EPF European Patients Forum

KAROLINSKA UNIVERSITY HOSPITAL

KING'S HEALTH PARTNERS

An Academic Health Science Centre for London

Partnering better health for all

Lilly

KNL Nederlandse Kankerorganisatie

KU LEUVEN

Pfizer

iHD The European Institute for Innovation through Health Data

UniSR Universitat de València

The Hyve

CHARITÉ

SANOFI

Vall d'Hebron

Erasmus MC